Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec

Executive Summary

Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month

You may also be interested in...



Novartis Oncology Pipeline Has Three Potential Blockbusters In The Offing

Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas

Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay

Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested

Prometheus Phase II Data For Novel TL1A Inhibitor Impresses On Efficacy

The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.

Latest News
See All
UsernamePublicRestriction

Register

PS048977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel